Top Small Cap Stocks To Consider - October 17th

Key Points

• Seven small-cap stocks to watch include Spring Valley Acquisition, Rani Therapeutics, Artiva Biotherapeutics, and others, indicating rising investor interest.
• These small-cap stocks typically have market capitalizations between $300 million and $2 billion, offering higher growth potential but with greater volatility and risk.
• Rani Therapeutics is developing an innovative oral delivery platform called the RaniPill capsule, which aims to facilitate the administration of various biologics.

Spring Valley Acquisition, Inflection Point Acquisition Corp. II, Rani Therapeutics, Artiva Biotherapeutics, SEALSQ, Lithium Americas, and Aadi Bioscience are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively low market capitalizations—typically in the roughly $300 million to $2 billion range, though exact cutoffs vary by index or fund. Investors often view them as offering higher growth potential but also greater volatility, lower liquidity, and higher risk compared with mid- or large-cap stocks. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Inflection Point Acquisition Corp. II (IPXX)

Read Our Latest Research Report on IPXX

Rani Therapeutics (RANI)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

Read Our Latest Research Report on RANI

Artiva Biotherapeutics (ARTV)

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Read Our Latest Research Report on ARTV

SEALSQ (LAES)

SEALSQ Corp, together with its subsidiaries, designs, develops, and markets semiconductor chips in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. It offers semiconductors, such as VaultIC secure elements, secure arm platform, and smart card reader chips; identity provisioning services, such as IoT device provisioning and chip provisioning; and managed PKI for IoT solutions and trust services.

Read Our Latest Research Report on LAES

Lithium Americas (LAC)

Lithium Americas Corp. engages in the exploration and development of lithium properties in the United States and Canada. It holds a 100% interest in the Thacker Pass project located in northern Nevada, as well as investments in exploration properties in the United States and Canada. Lithium Americas Corp.

Read Our Latest Research Report on LAC

Aadi Bioscience (AADI)

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Read Our Latest Research Report on AADI